Infinity Reports New Data from Phase 1b Trial of Saridegib in Patients with Pancreatic Cancer at ASCO-GI
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced updated data from the Phase 1b portion of an ongoing Phase 1b/2 clinical trial of saridegib (also known as IPI-926) in combination with the chemotherapy gemcitabine in patients with previously untreated, metastatic pancreatic cancer. These findings were presented during a poster session at the American Society of Clinical Oncology's 2012 Gastrointestinal Cancers Symposium (ASCO-GI) in San Francisco (Abstract #213) and support the ongoing Phase 2, double-blind, randomized, placebo-controlled trial comparing saridegib in combination with gemcitabine to placebo and gemcitabine.
In October 2011, Infinity announced the completion of enrollment in the Phase 2 portion of the trial, and the company expects to report topline Phase 2 data in the second half of 2012. The primary endpoint of the Phase 2 portion of the trial is overall survival.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.